Adjuvanted Schistosoma mansoni-Cathepsin B With Sulfated Lactosyl Archaeol Archaeosomes or AddaVax™ Provides Protection in a Pre-Clinical Schistosomiasis Model

Adjuvanted Schistosoma mansoni-Cathepsin B With Sulfated Lactosyl Archaeol Archaeosomes or AddaVax™ Provides Protection in a Pre-Clinical Schistosomiasis Model

Schistosomiasis threatens 800 million people worldwide. Chronic pathology manifests as hepatosplenomegaly, and intestinal schistosomiasis caused by Schistosoma mansoni can lead to liver fibrosis, cirrhosis, and blood in the stool. To assist the only FDA-approved drug, praziquantel, in parasite elimi...

Full description

Bibliographic Details
Main Authors: Dilhan J. Perera, Adam S. Hassan, Yimei Jia, Alessandra Ricciardi, Michael J. McCluskie, Risini D. Weeratna, Momar Ndao
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Immunology
Subjects:
Schistosoma mansoni
schistosomiasis
vaccine
adjuvant
archaeosomes
AddaVax
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.605288/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.605288/full

Similar Items